Building on technology from Stanford’s SPARK program, PSOMRI is developing MRI001, the first skin cell–targeted, immune-sparing therapy for inflammatory skin disease. MRI001 targets a keratinocyte ion channel, with initial proof-of-concept in the orphan disease pityriasis rubra pilaris (PRP), which currently has no approved therapies.